2025 United States Autoimmune Disease Treatment Market Revenue Opportunities Report
Description
The 2025 United States Autoimmune Disease Treatment Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autoimmune Disease Treatment Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the autoimmune disease treatment market in the United States are AbbVie Inc., Johnson & Johnson, Sanofi S.A., and Amgen Inc. AbbVie leads with a significant market share of around 16.6%, followed by Johnson & Johnson at 11.4%, Sanofi at 8.8%, and Amgen, which is also a major player with its portfolio including Enbrel for autoimmune diseases and significant revenue from these treatments. These companies dominate due to their extensive R&D pipelines, leading biologics, and immunotherapies for chronic autoimmune conditions such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Their activities include development and commercialization of biologics, biosimilars, and novel therapies. For instance, Amgen generates substantial revenue from Enbrel and other autoimmune drugs while focusing on innovation via clinical trials. Johnson & Johnson and Sanofi also apply personalized medicine and immunotherapy approaches to expand treatment options. The United States market's growth is fueled by high prevalence (over 23 million Americans affected), increasing awareness, and supportive healthcare infrastructure, with these companies leveraging product launches, acquisitions, and collaborations to enhance market presence.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autoimmune Disease Treatment Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the autoimmune disease treatment market in the United States are AbbVie Inc., Johnson & Johnson, Sanofi S.A., and Amgen Inc. AbbVie leads with a significant market share of around 16.6%, followed by Johnson & Johnson at 11.4%, Sanofi at 8.8%, and Amgen, which is also a major player with its portfolio including Enbrel for autoimmune diseases and significant revenue from these treatments. These companies dominate due to their extensive R&D pipelines, leading biologics, and immunotherapies for chronic autoimmune conditions such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Their activities include development and commercialization of biologics, biosimilars, and novel therapies. For instance, Amgen generates substantial revenue from Enbrel and other autoimmune drugs while focusing on innovation via clinical trials. Johnson & Johnson and Sanofi also apply personalized medicine and immunotherapy approaches to expand treatment options. The United States market's growth is fueled by high prevalence (over 23 million Americans affected), increasing awareness, and supportive healthcare infrastructure, with these companies leveraging product launches, acquisitions, and collaborations to enhance market presence.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
